Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the actemra (tocilizumab) market right now?

In recent times, the market size for actemra (tocilizumab) has experienced a swift expansion. The projected growth estimates a rise from $5,160 million in 2024 to $5,710 million in 2025, indicating a compound annual growth rate (CAGR) of 10.7%. This growth during the historical period can be associated with factors such as an increasing occurrence of autoimmune diseases, the growing use of biologic therapies, heightened awareness of chronic inflammatory conditions, robust regulatory approvals in primary markets, and the expansion of healthcare infrastructure in developed regions.

How fast Is the actemra (tocilizumab) market expected to grow, and what’s its future value?

It is anticipated that the actemra (tocilizumab) market will expand rapidly over the forthcoming years, expecting to reach $8,480 million by 2029, boasting a compound annual growth rate (CAGR) of 10.4%. The forthcoming growth is primarily due to factors such as the growing application of therapeutics like the COVID-19 cytokine release syndrome, an increased demand for personalized medicine, the creation and acceptance of biosimilars, escalating health care spending in budding markets, and heightening knowledge of biologic therapies in developing regions. Key trends for the predicted term encompass increased uptake of subcutaneous formulations, an emphasis on the development of biosimilars to reduce costs, progress in biotechnology for superior drug distribution systems, continuing clinical tests for new therapeutic indications, and strategic affiliations and investments by pharmaceutical firms.

Get your actemra (tocilizumab) market report here!

https://www.thebusinessresearchcompany.com/report/actemra-tocilizumab-global-market-report

What are the leading drivers of growth in the actemra (tocilizumab) market?

The increased occurrence of rheumatoid arthritis is predicted to boost the actemra (tocilizumab) market expansion in the upcoming years. Rheumatoid arthritis is a persistent autoimmune disease causing inflammation in joints, damage, and deterioration of life quality, impacting millions globally. Factors such as smoking, obesity, environmental exposures, and hormonal imbalances influence the disease. Actemra (tocilizumab) is applied in managing rheumatoid arthritis to mitigate inflammation and avert joint destruction by blocking the interleukin-6 (IL-6) receptor, particularly in patients who have not responded to other remedies. For example, in April 2024, the National Institute for Health and Care Research (NIHR), a government agency based in the UK, published data showing around 700,000 people in the UK were living with rheumatoid arthritis. Additionally, a report released in June 2024 by the Australian Institute of Health and Welfare, a national agency in Australia, stated that roughly 514,000 people (2.0% of the population) in Australia had rheumatoid arthritis in 2022. In 2023, rheumatoid arthritis constituted 2.0% of the complete disease load and 16% of the musculoskeletal conditions’ disease burden. Rheumatoid arthritis was also associated with 1,322 deaths in 2022, amounting to 5.1 deaths per 100,000 people, representing 0.7% of all fatalities. Hence, the increasing prevalence of rheumatoid arthritis propels the actemra (tocilizumab) market.

What are the key segments defining the actemra (tocilizumab) market?

The actemra (tocilizumab)market covered in this report is segmented –

1) By Product Type: Min Purity Less Than 98%; Min Purity 98%-99%; Min Purity More Than 99%

2) By Dosage: Injection; Solution; Concentrate

3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By Application: Cytokine Release Syndrome (CRS); Systemic Juvenile Idiopathic Arthritis (sJIA); Giant Cell Arteritis (GCA); Rheumatoid Arthritis (RA)

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19849&type=smp

Who are the key players steering the development of the actemra (tocilizumab) market?

Major companies operating in the actemra (tocilizumab) market include Roche Holding AG, Fresenius Kabi

What emerging trends are influencing the growth of the actemra (tocilizumab) market?

One primary trend in the actemra (tocilizumab) market is the focus on creating advanced solutions, such as tocilizumab biosimilar, to gain an industry advantage. These biosimilars are authorised for use in the treatment of autoimmune conditions and COVID-19, providing an alternative to the original drug, Actemra. For example, Fresenius Kabi, a healthcare entity based in Germany, introduced Tyenne, the inaugural tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union, in November 2023. Tyenne has been approved for the treatment of several immune and inflammatory diseases, including but not limited to, rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19849

Which regions are most influential in expanding the actemra (tocilizumab) market?

North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Narcotic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/narcotic-drugs-global-market-report

Narcotic Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/otic-drugs-global-market-report

Preeclampsia Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: